Evidence map›Paper›PMID 31447835›Full record

ArticleFrontiers in immunology2019

Exclusive Temporal Stimulation of IL-10 Expression in LPS-Stimulated Mouse Macrophages by cAMP Inducers and Type I Interferons.

Orna Ernst, Yifat Glucksam-Galnoy, Bibek Bhatta, Muhammad Athamna, Iris Ben-Dror, Yair Glick, Doron Gerber, Tsaffrir Zor

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Inhibitory effects ofHeliyon · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Orna ErnstDepartment of Biochemistry & Molecular Biology, School of Neurobiology, Biochemistry & Biophysics, Tel Aviv University, Tel Aviv, Israel.
Yifat Glucksam-GalnoyDepartment of Biochemistry & Molecular Biology, School of Neurobiology, Biochemistry & Biophysics, Tel Aviv University, Tel Aviv, Israel.
Bibek BhattaDepartment of Biochemistry & Molecular Biology, School of Neurobiology, Biochemistry & Biophysics, Tel Aviv University, Tel Aviv, Israel.
Muhammad AthamnaDepartment of Biochemistry & Molecular Biology, School of Neurobiology, Biochemistry & Biophysics, Tel Aviv University, Tel Aviv, Israel.
Iris Ben-DrorDepartment of Biochemistry & Molecular Biology, School of Neurobiology, Biochemistry & Biophysics, Tel Aviv University, Tel Aviv, Israel.
Yair GlickThe Nanotechnology Institute, Bar-Ilan University, Ramat Gan, Israel.
Doron GerberThe Nanotechnology Institute, Bar-Ilan University, Ramat Gan, Israel.
Tsaffrir ZorDepartment of Biochemistry & Molecular Biology, School of Neurobiology, Biochemistry & Biophysics, Tel Aviv University, Tel Aviv, Israel.
Tel Aviv University · ILBar-Ilan University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expression of the key anti-inflammatory cytokine IL-10 in lipopolysaccharide (LPS)-stimulated macrophages is mediated by a delayed autocrine/paracrine loop of type I interferons (IFN) to ensure timely attenuation of inflammation. We have previously shown that cAMP synergizes with early IL-10 expression by LPS, but is unable to amplify the late type I IFN-dependent activity. We now examined the mechanism of this synergistic transcription in mouse macrophages at the promoter level, and explored the crosstalk between type I IFN signaling and cAMP, using the β-adrenergic receptor agonist, isoproterenol, as a cAMP inducer. We show that silencing of the type I IFN receptor enables isoproterenol to synergize with LPS also at the late phase, implying that autocrine type I IFN activity hinders synergistic augmentation of LPS-stimulated IL-10 expression by cAMP at the late phase. Furthermore, IL-10 expression in LPS-stimulated macrophages is exclusively stimulated by either IFNα or isoproterenol. We identified a set of two proximate and inter-dependent cAMP response element (CRE) sites that cooperatively regulate early IL-10 transcription in response to isoproterenol-stimulated CREB and that further synergize with a constitutive Sp1 site. At the late phase, up-regulation of Sp1 activity by LPS-stimulated type I IFN is correlated with loss of function of the CRE sites, suggesting a mechanism for the loss of synergism when LPS-stimulated macrophages switch to type I IFN-dependent IL-10 expression. This report delineates the molecular mechanism of cAMP-accelerated IL-10 transcription in LPS-stimulated murine macrophages that can limit inflammation at its onset.

Indexed as

AnimalsCyclic AMPCyclic AMP Response Element-Binding ProteinInterferon Type IInterleukin-10IsoproterenolLipopolysaccharidesMacrophagesMicePromoter Regions, GeneticRAW 264.7 CellsResponse ElementsSp1 Transcription FactorCyclic AMPCyclic AMP Response Element-Binding ProteinInterferon Type IInterleukin-10IsoproterenolLipopolysaccharidesSp1 Transcription FactorcAMPcAMP response elementCREBIL-10 expressionIL-10 promoterlipopolysaccharidetoll-like receptor 4type I interferons

Identifiers

PMID31447835
PMCPMC6691811
OpenAlexW2959234623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.